Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

CStone's In-Licensed Cancer Treatment Meets Endpoints in Phase III Trial

publication date: May 23, 2019

Suzhou's CStone Pharma announced its in-licensed product, Tibsovo (ivosidenib), produced a substantial improvement in progression-free survival in previously treated patients with cholangiocarcinoma. The results came from a US Phase III trial of Tibsovo conducted by Agios, a Boston area pharma and CStone's partner. In June 2018, CStone acquired greater China rights to Tibsovo from Agios in a deal worth up to $424 million. Tibsovo is already approved in the US to treat acute myeloid leukemia (AML). More details....

Stock Symbols: (HK: 2616) (NSDQ: AGIO)

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here

BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here

Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here